APA (7th ed.) Citation

H, H., E, T., C, S., S, E., J, v. T., S, R., . . . S, S. (2023). Final analysis of the CLL2-GIVe trial: Obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut. Blood, 142(11), 961. https://doi.org/10.1182/blood.2023020013

Chicago Style (17th ed.) Citation

H, Huber, et al. "Final Analysis of the CLL2-GIVe Trial: Obinutuzumab, Ibrutinib, and Venetoclax for Untreated CLL with Del(17p)/TP53mut." Blood 142, no. 11 (2023): 961. https://doi.org/10.1182/blood.2023020013.

MLA (9th ed.) Citation

H, Huber, et al. "Final Analysis of the CLL2-GIVe Trial: Obinutuzumab, Ibrutinib, and Venetoclax for Untreated CLL with Del(17p)/TP53mut." Blood, vol. 142, no. 11, 2023, p. 961, https://doi.org/10.1182/blood.2023020013.